Company Milestones

After licensing the rights from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications, and subsequently entering into a cross license agreement with Cook Biotech, CorMatrix began its acceleration. In 2005, the Company received its first FDA clearance and shifted its focus from development stage to an integrated research, development and commercial entity. With significant patent protection, the Company is poised to successfully expand its current line of products.

• December 2012 — Cormatrix completes financing round
• November 2011 — Cormatrix receives full IDE approval from FDA for new onset post-operative atrial fibrillation clinical trial
• July 2011 — CorMatrix ECM for Carotid Repair receives FDA 510(k) clearance
• January 2010 — CorMatrix completes financing round
• April 2009 — CorMatrix begins expanded GLP study using ECM Emulsion
• December 2008 — CorMatrix ECM Technology implanted in more than 10,000 patients
• November 2008 – CorMatrix receives 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease from Frost Er Sullivan
• November 2008 – CorMatrix announces pre-clinical data suggesting next generation ECM Technology can improve cardiac function at the American Heart Association (AHA) Annual Meeting
• November 2008 – CorMatrix ECM for Pericardial Closure launches in Europe
• October 2008 – CorMatrix presents data on next generation ECM Technology at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference
• April 2008 — CorMatrix presents pre-clinical data suggesting ECM Technology can improve cardiac function at annual American College of Cardiology (ACC) Meeting
• February 2008 – CorMatrix ECM for Pericardial Closure receives CE mark
• February 2007 — CorMatrix ECM for Cardiac Tissue Repair receives 510(k) clearance
• March 2006 – First clinical implant of CorMatrix ECM for Pericardial Closure
• August 2005 – CorMatrix ECM for Pericardial Closure receives 510(k) clearance for reconstruction and repair of pericardium
• February 24, 2005 – CorMatrix and Cook Biotech enter cross-license agreement to encourage the development of cardiovascular devices using extracellular biomaterials
• 2001 – CorMatrix Cardiovascular, Inc. is founded